Answers are grounded in this paper and cite their sources.
Aim: Study was aimed to investigate the potential drug–drug interactions between antimalarial candidate 99/411 and antitubercular drug rifampicin. Methods: A single-dose drug-interaction study followed by multiple dose parallel study was designed to estimate the drug–drug interactions. Results: It was found that steady-state pharmacokinetics profile of 99/411 determined after multiple dosing for five successive days was consistent with the single-dose characteristics in both the cases, when 99/411 was given alone and co-administered with rifampicin. Conclusion: The compound was absorbed fast after each dosing and declined up to next 24 h to lower concentration. AUC showed accumulation of 99/411 day by day after multiple dosing, which may affect the therapeutic response of this molecule.
No takes yet. Share an insight, caveat, or question.
Hidau et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: